Testosterone protects from metabolic syndrome-associated prostate inflammation: An experimental study in rabbit

Journal of Endocrinology

Volumn 212, Issue 1, 2012, Pages 71-84

  Vignozzi, Linda ^a   Morelli, Annamaria ^a   Sarchielli, Erica ^a   Comeglio, Paolo ^a   Filippi, Sandra ^a   Cellai, Ilaria ^a   Maneschi, Elena ^a   Serni, Sergio ^a   Gacci, Mauro ^a   Carini, Marco ^a   Piccinni, Marie Pierre ^a   Saad, Farid ^c,d   Adorini, Luciano ^e   Vannelli, Gabriella B ^a   Maggi, Mario ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CIRMAR Centro Interuniversitario di Ricerca sulle basi molecolari della Malattie della Riproduzione   (Italy)

^c BAYER PHARMA AG   (Germany)

^d GULF MEDICAL UNIVERSITY   (United Arab Emirates)

^e INTERCEPT PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA SMOOTH MUSCLE ACTIN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOOXYGENASE 2; ESTRADIOL; FARNESOID X RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; MEMBRANE PROTEIN; MESSENGER RNA; OBETICHOLIC ACID; PROTEIN SERINE THREONINE KINASE; RETINOID RELATED ORPHAN RECEPTOR GAMMA; RHO ASSOCIATED COILED COIL CONTAINING KINASE TYPE 1; RHO ASSOCIATED COILED COIL CONTAINING KINASE TYPE 2; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIX TRANSMEMBRANE PROTEIN OF PROSTATE 2; TESTOSTERONE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA; TRANSGELIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; ESTRADIOL BLOOD LEVEL; EXPERIMENTAL RABBIT; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; HYPERTENSION; HYPOGONADISM; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPID DIET; MACROPHAGE; MALE; METABOLIC SYNDROME X; MYOFIBROBLAST; NEUTROPHIL; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROSTATITIS; PROTEIN EXPRESSION; T LYMPHOCYTE; TESTOSTERONE BLOOD LEVEL;

ANDROGENS; ANIMALS; BIOLOGICAL MARKERS; CHENODEOXYCHOLIC ACID; DIETARY FATS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ESTRADIOL; FIBROSIS; MALE; METABOLIC SYNDROME X; PROSTATE; PROSTATITIS; RABBITS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RNA, MESSENGER; TESTOSTERONE;

EID: 83455211370     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0289     Document Type: Article

References (73)

1. Amano T, Imao T, Takemae K, Iwamoto T & Nakanome M 2010 Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients. Aging Male 13 242-246.
2. Andersson KE, de GroatWC, McVary KT, Lue TF, MaggiM, RoehrbornCG, Wyndaele JJ, Melby T & Viktrup L 2011 Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourology and Urodynamics 30 292-301.
3. Ansar Ahmed S, Young PR & Penhale WJ 1986 Beneficial effect of testosterone in the treatment of chronic autoimmune thyroiditis in rats. Journal of Immunology 136 143-147.
4. Arteel GE, Thurman RG, Yates JM & Raleigh JA 1995 Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. British Journal of Cancer 72 889-895.
5. Bebo BF Jr 1999 Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. Journal of Immunology 162 35-40.
6. Bennewith KL, Raleigh JA & Durand RE 2002 Orally administered pimonidazole to label hypoxic tumor cells. Cancer Research 62 6827-6830.
7. Bouchentouf M, Benabdallah BF, Bigey P, Yau TM, Scherman D & Tremblay JP 2008 Vascular endothelial growth factor reduced hypoxia-induced death of human myoblasts and improved their engraftment in mouse muscles. Gene Therapy 15 404-414.
8. Corona G, Mannucci E, Forti G & Maggi M 2009 Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. International Journal of Andrology 32 587-598.
9. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E & Maggi M 2011a Testosterone and metabolic syndrome: a meta-analysis study. Journal of Sexual Medicine 8 272-283.
10. Corona G, Rastrelli G, Vignozzi L, Mannucci E & Maggi M 2011b Testosterone, cardiovascular disease and the metabolic syndrome. Best Practice & Research. Clinical Endocrinology & Metabolism 25 337-353.
11. De Lean A, Munson PJ & Rodbard D 1978 Simultaneous analysis of famiglie of sigmoidal curves: application to biomassa, radioligand assay, and physiological dose-response curves. American Journal of Physiology 235 97-102.
12. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB & Nelson WG 2007 Inflammation in prostate carcinogenesis. Nature Reviews. Cancer 7 256-269.
13. Donnell RF 2011 Benign prostate hyperplasia: a review of the year's progress from bench to clinic. Current Opinion in Urology 21 22-26.
14. Durand RE & Raleigh JA 1998 Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Research 58 3547-3550.
15. Fibbi B, Penna G, Morelli A, Adorini L & Maggi M 2010 Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. International Journal of Andrology 33 475-488.
16. Fijak M, Schneider E, Klug J, Bhushan S, Hackstein H & Schuler G 2011 Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: evidence for a direct role of testosterone on regulatory T cell expansion. Journal of Immunology 186 5162-5172.
17. Filippi S, Vignozzi L, Morelli A, Chavalmane AK, Sarchielli E, Fibbi B, Saad F, Sandner P, Ruggiano P, Vannelli GB et al. 2009 Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. Journal of Sexual Medicine 6 3274-3288.
18. Fox HS 1992 Androgen treatment prevents diabetes in nonobese diabetic mice. Journal of Experimental Medicine 175 1409-1412.
19. Gorbachinsky I, Akpinar H & Assimos DG 2010 Metabolic syndrome and urologic diseases. Reviews in Urology 12 e157-e180.
20. Haider A, Gooren LJ, Padungtod P & Saad F 2009 Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia 41 7-13.
21. Harbuz MS, Perveen-Gill Z, Lightman SL & Jessop DS 1995 A protective role for testosterone in adjuvant-induced arthritis. British Journal of Rheumatology 34 1117-1122.
22. Holmäng S, Mårin P, Lindstedt G & Hedelin H 1993 Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostatespecific antigen concentration in eugonadal middle-aged men. Prostate 2 99-106.
23. Kalinchenko S, Vishnevskiy EL, Koval AN, Mskhalaya GJ & Saad F 2008 Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male 11 57-61.
24. Karazindiyanoǧlu S & Çayan S 2008 The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male 11 146-149.
25. Kardassis D, Murphy C, Fotsis T, Moustakas A & Stournaras C 2009 Control of transforming growth factor beta signal transduction by small GTPases. FEBS Journal 276 2947-2965.
26. Krajewska M, Banares S, Zhang EE, Huang X, ScadengM, Jhala US, Feng GS & Krajewski S 2008 Development of diabesity in mice with neuronal deletion of Shp2 tyrosine phosphatase. American Journal of Pathology 172 1312-1324.
27. Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ & Thompson IM 2008 Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. American Journal of Epidemiology 168 1416-1424.
28. Laven BA, Orsini N, Andersson SO, Johansson JE, Gerber GS &Wolk A 2008 Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men. Journal of Urology 179 1891-1895.
29. Lédée N, Lombroso R, Lombardelli L, Selva J, Dubanchet J, Chaouat G, Frankenne F, Foidart JM, Maggi E, Romagnani S et al. 2008 Cytokines and chemokines in follicular fluids and potential of the corresponding embryo: the role of granulocyte colony-stimulating factor. Human Reproduction 23 2001-2009.
30. Legrand D, Elass E, CarpentierM& Mazurier J 2005 Lactoferrin: a modulator of immune and inflammatory responses. Cellular and Molecular Life Sciences 62 2549-2559.
31. Litman HJ, Steers WD, Wei JT, Kupelian V, Link CL, McKinlay JB & Boston Area Community Health Survey Investigators 2007 Relationship of lifestyle and clinical factors to lower urinary tract symptoms: results from Boston area community health survey. Urology 70 916-921.
32. Liva SM & Voskhul RR 2001 Testosterone acts directly on CD4CT lymphocytes to increase IL-10 production. Journal of Immunology 167 2060-2067.
33. Lorne E, Dupont H & Abraham E 2010 Toll-like receptors 2 and 4: initiators of non-septic inflammation in critical care medicine? Intensive Care Medicine 36 1826-1835
34. Lotti F, Corona G, Colpi GM, Filimberti E, Degli Innocenti S, Mancini M, Baldi E, Noci I, Forti G, Adorini L et al. 2011 Elevated body mass index correlates with higher seminal plasma interleukin 8 levels and ultrasonographic abnormalities of the prostate in men attending an andrology clinic for infertility. Journal of Endocrinological Investigation (In press).
35. Martin SA, Haren MT, Marshall VR, Lange K, Wittert GA & Members of the Florey Adelaide Male Ageing Study 2011 Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World Journal of Urology 29 179-184.
36. Michel MC, Mehlburger L, Schumacher H, Bressel HU & Goepel M 2000 Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. Journal of Urology 163 1725-1729.
37. Michel MC, Heemann U, Schumacher H, Mehlburger L & Goepel M 2004 Association of hypertension with symptoms of benign prostatic hyperplasia. Journal of Urology 172 1390-1393.
38. Miwa Y, Kaneda T & Yokoyama O 2008 Association between lower urinary tract symptoms and serum levels of sex hormones in men. Urology 72 552-555.
39. Mongiu AK & McVary KT 2009 Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity. Current Urology Reports 10 247-253.
40. Morelli A, Filippi S, Comeglio P, Sarchielli E, Chavalmane AK, Vignozzi L, Fibbi B, Silvestrini E, Sandner P, Gacci M et al. 2010a Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. Journal of Sexual Medicine 7 107-120.
41. Morelli A, Vignozzi L, Maggi M & Adorini L 2011 Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes. Biochimica et Biophysica Acta 1812 859-866.
42. Moul S & McVary KT 2010 Lower urinary tract symptoms, obesity and the metabolic syndrome. Current Opinion in Urology 20 7-12.
43. Nickel JC 1994 Prostatic inflammation in benign prostatic hyperplasia-the third component? Canadian Journal of Urology 1 1-4.
44. Parsons JK 2011 Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms. Current Opinion in Urology 21 1-4.
45. Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, Chavalmane A, Morelli A, Sarchielli E, Vannelli GB et al. 2009 The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate 69 480-493.
46. Pradidarcheep W 2008 Lower urinary tract symptoms and its potential relation with late-onset hypogonadism. Aging Male 11 51-55.
47. Quintar AA, Roth FD, De Paul AL, Aoki A & Maldonado CA 2006 Toll-like receptor 4 in rat prostate: modulation by testosterone and acute bacterial infection in epithelial and stromal cells. Biology of Reproduction 75 664-672.
48. Roberts RO, Jacobson DJ, Rhodes T, Klee GG, Leiber MM & Jacobsen SJ 2004 Serum sex hormones and measures of benign prostatic hyperplasia. Prostate 61 124-131.
49. Robinette CL 1988 Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. Prostate 12 271-286.
50. Rohrmann S, Smit E, Giovannucci E & Platz EA 2004 Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. American Journal of Epidemiology 159 390-397.
51. Saad F, Gooren L, Haider A & Yassin A 2007 An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Archives of Andrology 53 353-357.
52. Saad F, Gooren LJ, Haider A & Yassin A 2008 A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. Journal of Andrology 29 102-105.
53. Schatzl G, Brössner C, Schmid S, Kugler W, Roehrich M, Treu T, Szalay A, Djavan B, Schmidbauer CP, Söregi S et al. 2000 Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology 55 397-402.
54. Seim A, Hoyo C, Ostbye T & Vatten L 2005 The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. British Journal of Urology International 96 88-92.
55. Sfanos KS, Wilson BA, De Marzo AM & Isaacs WB 2009 Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. PNAS 106 3443-3448.
56. Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y, Mizokami A, Koh E, Origasa H, Iwamoto T et al. 2011 Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male 14 53-58.
57. Sims GP, Rowe DC, Rietdijk ST, Herbst R & Coyle AJ 2010 HMGB1 and RAGE in inflammation and cancer. Annual Review of Immunology 28 367-388.
58. St Sauver JL, Jacobson DJ, McGree ME, Girman CJ, Klee GG, Lieber MM & Jacobsen SJ 2011 Associations between longitudinal changes in serum estrogen, testosterone, and bioavailable testosterone and changes in benign urologic outcomes. American Journal of Epidemiology 173 787-796.
59. Tan AH, Gilling PJ, Kennett KM, Fletcher H & Fraundorfer MR 2003 Longterm results of high-power holmium laser vaporization (ablation) of the prostate. British Journal of Urology International 92 707-709.
60. Tangbanluekal L & Robinette CL 1993 Prolactin mediates estradiol-induced inflammation in the lateral prostate of Wistar rats. Endocrinology 132 2407-2416.
61. Tomita K, Mizoue T & Matsumoto T 2009 Lower urinary tract symptoms in relation to lifestyle and medical conditions in Japanese workers. International Journal of Urology 16 493-498.
62. Traish AM, Miner MM, Morgentaler A & Zitzmann M 2011 Testosterone deficiency. American Journal of Medicine 124 578-587.
63. Trifiro MD, Parsons JK, Palazzi-Churas K, Bergstrom J, Lakin C & Barrett-Connor E 2010 Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. British Journal of Urology International 105 1554-1559.
64. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, Taylor K, Klein E, Manjunatha U, Gonzales J et al. 2008 Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infection and Immunity 76 2333-2340.
65. Vignozzi L, Filippi S, Morelli A, Ambrosini S, Luconi M, Vannelli GB, Donati S, Crescioli C, Zhang XH, Mirone V et al. 2006 Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. Journal of Sexual Medicine 3 419-431.
66. Vignozzi L, Morelli A, Filippi S, Vannelli GB, Mungai S, Marini M, Boddi V, Forti G & Maggi M 2008 Effect of sildenafil administration on penile hypoxia induced by cavernous neurotomy in the rat. International Journal of Impotence Research 20 60-67.
67. Vignozzi L, Filippi S, Morelli A, Marini M, Chavalmane A, Fibbi B, Silvestrini E, Mancina R, Carini M, Vannelli GB et al. 2009 Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism. Journal of Sexual Medicine 6 1270-1283.
68. Vignozzi L, Morelli A, Filippi S, Comeglio P, Chavalmane AK, Marchetta M, Toce M, Yehiely-Cohen R, Vannelli GB, Adorini L et al. 2011 Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. Journal of Sexual Medicine 8 57-77.
69. Wang ZH, Zhang W, Gong HP, Guo ZX, Zhao J, Shang YY, Feng JB, Zhang Y & Zhong M 2010 Expression of STAMP2 in monocytes associates with cardiovascular alterations. European Journal of Clinical Investigation 40 490-496.
70. Yanamandra K, Alexeyev O, Zamotin V, Srivastava V, Shchukarev A, Brorsson AC, Tartaglia GG, Vogl T, Kayed R, Wingsle G et al. 2009 Amyloid formation by the pro-inflammatory S100A8/A9 proteins in the ageing prostate. PLoS ONE 4 e5562-e5576.
71. Yatkin E, Bernoulli J, Talvitie EM & Santti R 2009 Inflammation and epithelial alterations in rat prostate: impact of the androgen to oestrogen ratio. International Journal of Andrology 32 399-410.
72. Zhu J, Yamane H & Paul WE 2010 Differentiation of effector CD4 T cell populations. Annual Review of Immunology 28 445-489.
73. Zitzmann M 2009 Testosterone deficiency, insulin resistance and the metabolic syndrome. Nature Reviews. Endocrinology 5 673-681.